AHI
Advanced Health Intelligence Ltd.
stock NASDAQ

That is your opinion and it is not science based, so you already contradicted one point you made, also with simple arguments it has been demonstrated that with basic scientific knowledge, what you say is an outright lie, even those studies you shared say AHI can be complemented with other metrics, but they don’t say anything else. You say this is a bad play… for whom? For the one shorting the stock?

The market potential for IHL-42X is multibillion-dollar if it becomes an FDA-approved drug for OSA. Even a small slice of the market could exceed Incannex’s current valuation by many multiples.
If the CSR shows consistent AHI decreases across subgroups and low dropouts, odds rise. We need to wait for this.
With current cash they would run out within a year even without launching Phase 3.
To fund a Phase 3, they will almost certainly need equity raise and/or strategic partner (big pharma licensing or co-funding deal)
Incannex hasn’t disclosed any confirmed Big Pharma partner for IHL-42X. They did partner with Alfred and Novotech back in 2020 for early-phase work, but there’s no public licensing deal now. But they seem to have FDA clearance to start Phase 3, so they could be planning a partnership soon.
Apnimed’s AD109 already has strong Phase-3 results (mean AHI ≈ −47% at 26 weeks, sustained to 51 weeks) and is leading the race. IHL-42X is promising but still needs trials and durability data to catch up.
Apnimed has an estimated market cap (based on private placements) of around $400M while Incannex is at $60M.
It will be interesting.

You have a serious problem interpreting nuance.
AHI is the industry standard. That isn't a statement that it's perfect or could never be improved in the future. However, it's standard expectation that any treatments of sleep apnea will have to address AHI.
Imagine the alternative. If IXHL released topline data with their own invented metrics instead of using the industry standard, it obviously would have raised red flags. The Apnimed study for their oral drug also used AHI. Qualification for an implant device requires a certain AHI score. Etc, etc. It's the industry standard.
If referencing AHI is such a big deal to you, then you should never look at investing in any treatment for sleep apnea. That's fine but leave the rest of us alone.

Yes, because it's actual factual science, and you have yet to link one study showing the opposite of AHI being a great metric by which to judge things.

8
Apnea-Hypopnea Index (AHI)
The Apnea-Hypopnea Index (AHI) is a metric used to measure the severity of sleep apnea by counting the average number of complete cessations of breathing (apneas) and partial reductions in airflow (hypopneas) per hour of sleep, typically performed during a polysomnogram. An AHI score is classified into severity levels: Normal (<5 events/h), Mild (5–15 events/h), Moderate (15–30 events/h), and Severe (>30 events/h). This index helps doctors diagnose sleep apnea and determine the most appropriate treatment plan for a patient.

How AHI is Calculated and Used
Calculation:
The total number of apneas and hypopneas is divided by the total hours of sleep recorded during a sleep study (polysomnogram).
What it Measures:
An apnea is a complete stop in breathing, while a hypopnea is a significant reduction in airflow that lasts for at least 10 seconds.
Purpose:
The AHI score helps classify the severity of sleep apnea, which guides the selection of treatment options.
Sleep Apnea Severity Levels
Normal: Fewer than 5 events per hour.
Mild: An AHI of 5 to 15 events per hour.
Moderate: An AHI of 15 to 30 events per hour.
Severe: An AHI of more than 30 events per hour.

I don't need to be a chef to know I'm being served shit.
All the credentials in the world doesn't change that. They chose to lead with quality of life metrics, they chose to lead with a focus on AHI as their best metric. Literally the topline readout is there to be looked at and interrogated. They failed.
If you go on about how phase 2/2b trials aren't about testing efficacy as their endpoint then I'll know you don't know what you're talking about. The 2b portion of a trial testing dosage is about finding the dose they want as their candidate leading into phase 3. Neither the high dose or low dose demonstrated any efficacy in what will be the phase 3 primary endpoint of reducing OSA.

That is your opinion and it is not science based, so you already contradicted one point you made, also with simple arguments it has been demonstrated that with basic scientific knowledge, what you say is an outright lie, even those studies you shared say AHI can be complemented with other metrics, but they don’t say anything else. You say this is a bad play… for whom? For the one shorting the stock?

The market potential for IHL-42X is multibillion-dollar if it becomes an FDA-approved drug for OSA. Even a small slice of the market could exceed Incannex’s current valuation by many multiples.
If the CSR shows consistent AHI decreases across subgroups and low dropouts, odds rise. We need to wait for this.
With current cash they would run out within a year even without launching Phase 3.
To fund a Phase 3, they will almost certainly need equity raise and/or strategic partner (big pharma licensing or co-funding deal)
Incannex hasn’t disclosed any confirmed Big Pharma partner for IHL-42X. They did partner with Alfred and Novotech back in 2020 for early-phase work, but there’s no public licensing deal now. But they seem to have FDA clearance to start Phase 3, so they could be planning a partnership soon.
Apnimed’s AD109 already has strong Phase-3 results (mean AHI ≈ −47% at 26 weeks, sustained to 51 weeks) and is leading the race. IHL-42X is promising but still needs trials and durability data to catch up.
Apnimed has an estimated market cap (based on private placements) of around $400M while Incannex is at $60M.
It will be interesting.

You have a serious problem interpreting nuance.
AHI is the industry standard. That isn't a statement that it's perfect or could never be improved in the future. However, it's standard expectation that any treatments of sleep apnea will have to address AHI.
Imagine the alternative. If IXHL released topline data with their own invented metrics instead of using the industry standard, it obviously would have raised red flags. The Apnimed study for their oral drug also used AHI. Qualification for an implant device requires a certain AHI score. Etc, etc. It's the industry standard.
If referencing AHI is such a big deal to you, then you should never look at investing in any treatment for sleep apnea. That's fine but leave the rest of us alone.

Yes, because it's actual factual science, and you have yet to link one study showing the opposite of AHI being a great metric by which to judge things.

8
Apnea-Hypopnea Index (AHI)
The Apnea-Hypopnea Index (AHI) is a metric used to measure the severity of sleep apnea by counting the average number of complete cessations of breathing (apneas) and partial reductions in airflow (hypopneas) per hour of sleep, typically performed during a polysomnogram. An AHI score is classified into severity levels: Normal (<5 events/h), Mild (5–15 events/h), Moderate (15–30 events/h), and Severe (>30 events/h). This index helps doctors diagnose sleep apnea and determine the most appropriate treatment plan for a patient.

How AHI is Calculated and Used
Calculation:
The total number of apneas and hypopneas is divided by the total hours of sleep recorded during a sleep study (polysomnogram).
What it Measures:
An apnea is a complete stop in breathing, while a hypopnea is a significant reduction in airflow that lasts for at least 10 seconds.
Purpose:
The AHI score helps classify the severity of sleep apnea, which guides the selection of treatment options.
Sleep Apnea Severity Levels
Normal: Fewer than 5 events per hour.
Mild: An AHI of 5 to 15 events per hour.
Moderate: An AHI of 15 to 30 events per hour.
Severe: An AHI of more than 30 events per hour.

I don't need to be a chef to know I'm being served shit.
All the credentials in the world doesn't change that. They chose to lead with quality of life metrics, they chose to lead with a focus on AHI as their best metric. Literally the topline readout is there to be looked at and interrogated. They failed.
If you go on about how phase 2/2b trials aren't about testing efficacy as their endpoint then I'll know you don't know what you're talking about. The 2b portion of a trial testing dosage is about finding the dose they want as their candidate leading into phase 3. Neither the high dose or low dose demonstrated any efficacy in what will be the phase 3 primary endpoint of reducing OSA.